Cybin Announces Transfer of U.S. Listing to Nasdaq with Ticker Change to HELP

Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage pharmaceutical company developing next-generation mental health treatments, announced plans to voluntarily transfer its U.S. stock exchange listing from NYSE American to the Nasdaq Global Market. The Company expects its common shares to cease trading on NYSE American at market close on Jan. 4, 2026, and to begin trading on Nasdaq at market open on Jan. 5, 2026, at which time the ticker symbol will change from "CYBN" to "HELP." Cybin will remain listed on Cboe Canada and will also trade under the "HELP" ticker on that exchange beginning Jan. 5, 2026.

This strategic move to Nasdaq represents a significant milestone for Cybin as it advances its clinical programs. The company is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. With promising class leading data, Cybin is working to change the mental health treatment landscape through the introduction of novel drugs that provide effective and durable results for patients.

The timing of this exchange transfer coincides with Cybin's progress in its clinical development pipeline. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, Cybin is advancing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds.

The change to the "HELP" ticker symbol is particularly meaningful as it directly reflects the company's mission to address mental health challenges. This symbolic change aligns with Cybin's operational presence in Canada, the United States, the United Kingdom and Ireland since its founding in 2019. Nasdaq's reputation as a premier exchange for growth-oriented companies, particularly in the biotechnology and pharmaceutical sectors, provides Cybin with enhanced visibility among institutional investors and analysts who follow the mental health treatment space.

For investors seeking additional information, the latest news and updates relating to CYBN are available in the company's newsroom at https://ibn.fm/CYBN. The transfer announcement was disseminated through specialized communications platforms including InvestorWire, which is one of 75+ brands within the Dynamic Brand Portfolio that delivers advanced wire-grade press release syndication for private and public companies and the investment community. Additional details about these communication services can be found at https://www.InvestorWire.com.